Post-Abrasion Opioid Request and PDMP Red Flags
Dr. Marcus Chen, OD, sees a 34-year-old welder two days after removing a metallic corneal foreign body. The abrasion is healing, but the patient rates pain 8/10, asks for "oxycodone like the urgent care gave me," and says the 12 tablets are gone. A PDMP check shows a hydrocodone prescription from an urgent care 10 days ago and a buprenorphine prescription from an addiction clinic that the patient did not disclose. The patient becomes irritable when asked about the buprenorphine, says he "just needs to work," and threatens a bad online review. Dr. Chen has a DEA registration and Oregon prescribing authority. He considers a small hydrocodone prescription to "tide him over" plus a referral. The practice has no written opioid policy. Oregon's PDMP query is documented.
1. Analyze whether Dr. Chen may or should prescribe a controlled substance here. Which legal authorities and clinical facts drive the answer?
Read the worked answer
Authority is not a mandate. An Oregon optometrist with a DEA registration may prescribe controlled substances for conditions within the scope of optometric practice, but federal and state law require a legitimate medical purpose, an adequate evaluation, PDMP review where required, and documentation. The red flags are substantial: an early refill request, 12 tablets reportedly gone in two days, undisclosed buprenorphine, irritability, and a request for a specific opioid. Buprenorphine commonly signals treatment for opioid use disorder; adding an opioid could be dangerous and is a serious caution.
A small "tide over" prescription without a clear ocular indication and a plan is likely below the professional standard. Dr. Chen should not prescribe merely to avoid a bad review. He can offer non-opioid analgesia, re-examine the abrasion, refer to primary care or addiction and pain management, and document the reasoning. If he concludes a controlled substance is clinically indicated, he must check the PDMP as Oregon law requires for opioids, use the lowest effective dose, counsel on risks, and document the rationale. On these facts, declining is the defensible course.
2. What documentation and communication steps are required if he declines to prescribe?
Read the worked answer
Decline clearly and nonjudgmentally. Explain that the eye findings do not justify an opioid and that mixing an opioid with buprenorphine is risky. Offer alternatives, make a referral, and give written instructions. Document the refusal, the PDMP result, the clinical findings, and the offer of referral. Do not discharge the patient solely because of substance use without a safe termination plan; if behavior makes the relationship unsafe, give written notice, arrange emergency coverage, and provide records. A patient cannot be abandoned mid-treatment.
If the patient threatens a review, record that fact objectively; it does not change clinical judgment. Respond professionally to any online review without disclosing protected health information. The nondisclosure of buprenorphine is clinically material, so ask again in a nonjudgmental way and document the answer. Dr. Chen should also consider adopting a written controlled-substance policy covering PDMP checks, refill rules, and referral expectations.
3. Does the threatened online review change Dr. Chen's legal or ethical obligations? Explain.
Read the worked answer
No. A threatened review is not a legal basis to prescribe a controlled substance, and prescribing to avoid criticism could itself be unprofessional conduct. The obligations run to the patient's clinical needs and to the public, not to the practice's online reputation. If the patient posts a review, Dr. Chen may respond in general terms but must not reveal that the patient received buprenorphine, was refused opioids, or has a substance use disorder. Those facts are protected health information.
He should keep the clinical record factual and avoid retaliatory language. If the review contains false statements, he can consult the platform's process or counsel, but he should not trade patient confidentiality for reputation. The Board evaluates whether the prescribing decision was clinically and legally sound, not whether the patient was satisfied.